U.S. Specialty Stores Stock News

Reddit (NYSE:RDDT) has approved a $1b share repurchase program, aiming to buy back its own stock over time. The company has also been fined £14.47m by the UK's Information Commissioner's Office for child data privacy violations. These developments come as Reddit's share price stands at $136.0 after a 9.6% gain over the past week and a 43.8% decline year to date. Reddit's recent moves present a mixed picture to consider. On one side, the $1b buyback signals that management is prepared to...

VICI Properties Inc. recently expanded its role in the One Beverly Hills project by providing a US$1.50 billion mezzanine loan behind a US$2.80 billion senior facility and agreed to acquire casino and hotel real estate in Alberta that will be folded into its existing triple-net master lease with PURE. Together, these moves deepen VICI’s exposure to high-end experiential real estate while extending long-term, inflation-linked rental streams from both U.S. luxury mixed-use and Canadian gaming...

If you are wondering whether JD.com's current share price offers value or just extra risk, this breakdown will help you make sense of where the stock stands today. JD.com closed at US$28.46, with returns of a 1.7% decline over 7 days, 5.3% over 30 days, a 3.6% decline year to date, a 16.1% decline over 1 year, a 24.7% decline over 3 years, and a 60.2% decline over 5 years, which may change how you think about its potential and risk. Recent coverage of JD.com has focused on its position in...

Baxter International (BAX) has launched its IV Verify Line Labeling System at the 2026 American Organization for Nursing Leadership Conference, highlighting a new automation tool aimed at IV line identification, medication safety, and nurse workflow efficiency. See our latest analysis for Baxter International. Despite the IV Verify launch highlighting Baxter International's focus on bedside safety and workflow tools, the shares trade at US$16.68 after a 5.6% 7 day share price gain but a 41.0%...

Terreno Realty (TRNO) has been drawing fresh attention after recent share moves, with the stock up about 2.5% over the past week but slightly lower over the past month. See our latest analysis for Terreno Realty. The recent 2.5% 7 day share price return sits alongside a 5.3% year to date share price return and a 20.5% 1 year total shareholder return, which suggests momentum is building rather than fading. If this kind of steady trend interests you, it could be a good moment to broaden your...

In early April 2026, Baron Capital reiterated its positive stance on Host Hotels & Resorts in its Q4 2025 fund letter, while the company also received Nareit’s 2026 Leader in the Light Award for Operations for large-cap REITs, recognizing its sustainability and operational practices. Together, the institutional endorsement and sustainability recognition underscore how Host links environmental and social initiatives with financial discipline, strengthening its appeal to long-term, ESG-focused...

We can readily understand why investors are attracted to unprofitable companies. Indeed, vTv Therapeutics ( NASDAQ:VTVT...

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Onto Innovation recently reported that strong demand for its metrology and inspection tools in AI and advanced semiconductor packaging, supported by a record backlog and a major volume agreement with a leading HBM maker, is driving expectations for more than 30% revenue growth in advanced packaging in 2026. This momentum not only reinforces Onto Innovation’s role in critical AI and high‑bandwidth memory production, but also highlights how higher-margin advanced packaging tools and improving...

Procore Technologies (PCOR) has reshuffled its top leadership, naming Rachel Pyles as Chief Financial Officer and Walt Hearn as Chief Revenue Officer, while reaffirming its 2026 guidance and continued focus on AI driven platform expansion. See our latest analysis for Procore Technologies. The leadership reshuffle comes as the share price trades at US$58.02, with a 7 day share price return of 4.05% and a 90 day share price return showing a 22.14% decline, while the 3 year total shareholder...

In early April 2026, Alkermes plc announced it had begun the Brilliance phase 3 program, a set of randomized, double-blind, placebo-controlled studies testing its oral orexin 2 receptor agonist alixorexton in adults with narcolepsy type 1 and type 2, following earlier phase 1 and phase 2 work and Breakthrough Therapy designation in narcolepsy type 1. The launch of these Brilliance Studies signals Alkermes’ intention to build a differentiated sleep-disorder franchise around orexin agonism,...

Recently, First Financial Bankshares’ board of directors promoted David Bailey to CEO and reported a record quarterly net income with strong deposit growth, while absorbing a US$21.55 million credit loss tied to fraudulent activity by a commercial borrower. This combination of leadership transition and resilient financial performance offers insight into how the bank is managing risk while pursuing its growth plans. We’ll explore how Bailey’s appointment and the record quarterly results shape...

Recent share performance and business mix Markel Group (MKL) has recently drawn attention after a one-month return of about a 4% decline and a past three-month return of roughly an 11% decline, contrasting with a positive one-year total return of 13.1%. The company operates across insurance and a range of industrial and consumer businesses. Markel Insurance generates about US$10.3b of revenue, alongside contributions from the Industrial, Consumer and Other, Financial, and Corporate...

Keybanc analyst Aleksey Yefremov recently shifted his rating on Avient (AVNT) from Overweight to Sector Weight, a change that puts fresh attention on how the stock compares with its peers. See our latest analysis for Avient. Avient shares recently pulled back, with a 1 day share price return of a 3.65% decline and a 30 day share price return of a 4.15% decline. However, the 1 year total shareholder return of 21.30% and the year to date share price return of 10.60% suggest momentum has...

Lindsay (LNN) is back in focus after reporting quarterly results that missed analyst expectations, with softer demand in both Irrigation and Infrastructure, weaker operating margins, and management flagging limited near term growth catalysts. See our latest analysis for Lindsay. The weak quarter has been followed by a sharp reset in expectations, with a 1 month share price return showing a decline of 20.51% and a 1 year total shareholder return showing a loss of 12.90%, pointing to fading...

EnerSys (ENS) has drawn attention after announcing the closure of its legacy lead-acid battery plant in Tijuana, with production shifting to its Thin Plate Pure Lead facility in Springfield, Missouri. See our latest analysis for EnerSys. The stock’s recent 14.32% 1 month share price return and 17.66% year to date share price return suggest momentum has been building, while the 120.67% 1 year total shareholder return points to stronger gains over a longer stretch. If you are looking beyond...

MARA Holdings (MARA) is shaking up its business model after selling 15,133 Bitcoin for about US$1.1b, cutting its workforce by 15%, and retiring roughly 30% of its convertible debt. See our latest analysis for MARA Holdings. The latest restructuring news has arrived alongside a 1 day share price return of 8.33% and a 7 day share price return of 11.74%. However, the 1 year total shareholder return of 22.65% and 5 year total shareholder return of 82.60% indicate that longer term momentum has...

In March 2026, Elastic announced that Elastic Cloud Hosted on AWS GovCloud (US) achieved FedRAMP High authorization, enabling U.S. federal agencies to run sensitive, high-impact workloads for security, Zero Trust, and AI-powered mission applications on a standardized, rigorously vetted cloud platform. Elastic also introduced Elastic Workflows as a native automation layer inside Elastic Security, aiming to replace standalone SOAR tools by combining scripted playbooks with AI agents that act...

In March 2026, Brightstar Lottery PLC entered into new senior secured multicurrency revolving credit facilities totaling US$650 million and €1,000 million, aligning covenants across its major debt agreements and refinancing older facilities to support general corporate purposes. By locking in a five-year funding backstop with terms linked to its public credit ratings, Brightstar Lottery has materially expanded its financial flexibility and tightened the link between its borrowing costs and...

Valley National Bancorp (VLY) is back in focus after JPMorgan reiterated its Overweight rating while trimming its price target, as investors weigh the bank’s 25 million share buyback and broader capital plans. See our latest analysis for Valley National Bancorp. That reassessment has cooled very short term enthusiasm, with a 1 day share price return of a 0.16% decline, but the 7 day share price return of 4.37% and 1 year total shareholder return of 59.59% suggest momentum has been building...

Relay Therapeutics recently announced that initial clinical and preclinical data for its PI3Kα inhibitor zovegalisib in vascular anomalies will be presented at the International Society for the Study of Vascular Anomalies World Congress 2026 in May, based on results that supported advancing the regimen into the ongoing Phase 3 ReDiscover-2 trial. By aiming a mutant-selective PI3Kα inhibitor at both PIK3CA-driven vascular anomalies and certain breast cancers, Relay Therapeutics is linking a...

In late March 2026, Johnson & Johnson reported 52-week Phase 3 data showing its oral peptide ICOTYDE maintained high complete skin clearance rates and a consistent safety profile in adults and adolescents with moderate-to-severe plaque psoriasis, while Royalty Pharma announced a US$500 million R&D co-funding agreement to advance JNJ-4804 for autoimmune diseases. These developments highlight Johnson & Johnson’s push to build a differentiated immunology portfolio, pairing late-stage oral...

The latest move for Nuvation Bio (NUVB) centers on Europe, where the European Medicines Agency has validated the Marketing Authorisation Application for taletrectinib in advanced ROS1-positive non-small cell lung cancer. See our latest analysis for Nuvation Bio. The EMA validation comes shortly after Nuvation Bio secured global rights to safusidenib in Japan, against a backdrop of a 7 day share price return of 8.89% but a 90 day share price return decline of 48.06%, while the 1 year total...

Centene Corporation recently announced that, effective March 18, 2026, long-time finance executive and CPA Theodore Pienkos became Corporate Controller and Chief Accounting Officer, while prior controller Kate Casso moved into a new Senior Vice President role overseeing finance operations and innovation. These leadership shifts arrive as Centene faces pressure from elevated Medicaid and ACA marketplace medical costs and the company’s decision to withdraw its 2025 guidance, placing extra...